** Shares in Fresenius Medical Care FMEG.DE dive around 7% after the German dialysis specialist issued cautious 2026 targets despite Q4 core earnings beat
** Quarterly operating income excluding special items jumped 44% to 705 million euros ($830 million), significantly beating analysts' expectations for 633 million
** FMC expects 2026 sales to remain stable year-on-year, and adjusted operating income to come at a mid‑single‑digit percent drop and a mid‑single‑digit percent rise
** "Blowout Q4 raises the growth bar for 2026," J.P.Morgan says in a note
** JPM expects low-single-digit EBIT downgrades to consensus for 2026
** "We see the shares up LSD initially, but then expect them to fade on the FY26 downgrades and expectations of further parent sell downs," JPM adds
** Shares are on track for worst day since early November 2025, if losses hold
** Stock among worst performers on Stoxx 600 .STOXX
($1 = 0.8497 euros)
(Reporting by Maria Rugamer)
((Maria.Rugamer@thomsonreuters.com))